Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2a double-blind placebo-controlled trial of IM-250 in recurrent genital herpes
2024-516368-27-00Phase 2Authorised
- Sponsor
- Innovative Molecules GmbH
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in genital herpes and herpes simplex virus type 2 (HSV-2) comparing IM-250 with Placebo (2 arms). Planned start Jan 2025; status: authorised.
02
Drugs
adibelivir
03
Conditions
genital herpesherpes simplex virus type 2 (HSV-2)
Beyond the preview
Go deeper on 2024-516368-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516368-27-00.